Tema Cardiovascular and Metabolics ETF Rating $30.79 -0.09 (-0.29%) (As of 10:25 AM ET) Add Compare Share Share Ratings Stock AnalysisChartHeadlinesHoldingsOwnershipRatingsShort InterestTrends Tema Cardiovascular and Metabolics ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.HRTS Aggregate RatingModerate Buy 2.78Holdings in HRTS have an aggregate rating of Moderate Buy based on 491 analyst ratings issued in the past year covering 38 companies (84.9% of the portfolio).HRTS Aggregate Price Target$30.69-0.32% DownsideHigh Prediction$30.69Average Prediction$30.69Low Prediction$30.69Holdings in HRTS have an aggregate price target of $30.69 and a range of $30.69 to $30.69 covering 38 companies (84.9% of the portfolio).HRTS Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy13 Buy rating(s)Moderate Buy21 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Tema Cardiovascular and Metabolics ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 38 HRTS Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings7.92%AMGNAmgen$285.42-0.9%4.9132 of 5 stars2.46$333.57 16.9%26Ex-DividendShort Interest ↓Positive News5.49%LLYEli Lilly and Company$743.60-1.3%4.9913 of 5 stars2.81$1,007.94 35.5%21Analyst Revision5.29%ALNYAlnylam Pharmaceuticals$248.40-0.2%4.3981 of 5 stars2.71$298.09 20.0%24Analyst Forecast4.97%VRTXVertex Pharmaceuticals$447.02-0.9%4.0527 of 5 stars2.53$499.12 11.7%30Analyst DowngradeNews CoveragePositive News3.66%CRNXCrinetics Pharmaceuticals$55.94-0.2%3.5524 of 5 stars2.91$70.18 25.5%11Analyst Revision3.63%BBIOBridgeBio Pharma$22.90-0.6%4.5795 of 5 stars2.87$47.57 107.7%15Insider TradeAnalyst Revision3.16%CYTKCytokinetics$49.17-1.4%4.025 of 5 stars2.75$83.93 70.7%16Analyst ForecastInsider TradeOptions VolumeNews Coverage2.84%MDTMedtronic$84.56+0.5%4.9595 of 5 stars2.44$95.19 12.6%18Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage2.73%REGNRegeneron Pharmaceuticals$738.30-0.7%4.7877 of 5 stars2.78$1,099.55 48.9%23Positive News2.66%MREOMereo BioPharma Group$3.56-0.6%2.9665 of 5 stars3.20$7.50 110.7%5Analyst RevisionNews Coverage2.51%MASIMasimo$166.80+1.1%4.0735 of 5 stars2.71$163.67 -1.9%72.50%IONSIonis Pharmaceuticals$35.19-0.6%4.2328 of 5 stars2.68$60.65 72.3%192.50%BSXBoston Scientific$91.05+1.0%4.6004 of 5 stars2.91$93.39 2.6%23Analyst Forecast2.24%GPCRStructure Therapeutics$31.38-4.1%2.3001 of 5 stars3.00$86.80 176.6%6Analyst Revision2.15%RAREUltragenyx Pharmaceutical$46.77+0.8%4.6424 of 5 stars2.92$86.69 85.4%132.12%MIRMMirum Pharmaceuticals$42.84-1.9%4.312 of 5 stars3.17$57.73 34.8%12Analyst Revision2.10%MLYSMineralys Therapeutics$12.13-3.7%2.9873 of 5 stars3.00$30.00 147.3%32.05%ASNDAscendis Pharma A/S$123.08-1.0%3.0066 of 5 stars2.92$191.77 55.8%13Analyst Upgrade2.04%RCKTRocket Pharmaceuticals$12.81-1.8%4.4162 of 5 stars2.91$51.00 298.1%11Analyst ForecastAnalyst Revision2.03%KROSKeros Therapeutics$53.89-0.5%3.4913 of 5 stars3.00$88.89 64.9%122.01%PODDInsulet$263.00-1.3%4.3999 of 5 stars2.80$253.27 -3.7%15Positive News1.98%DXCMDexCom$74.68-0.7%4.9841 of 5 stars2.72$104.59 40.0%18Positive News1.94%EWEdwards Lifesciences$69.91+0.5%4.1267 of 5 stars2.38$75.67 8.2%26Short Interest ↓Analyst Revision1.59%NTLAIntellia Therapeutics$13.54+3.2%4.5424 of 5 stars2.72$54.94 305.7%18Analyst ForecastAnalyst Revision1.59%ARWRArrowhead Pharmaceuticals$18.39-1.7%3.5956 of 5 stars2.70$45.33 146.5%10Upcoming EarningsAnalyst Forecast1.32%AKROAkero Therapeutics$30.24-1.3%4.0631 of 5 stars2.88$46.83 54.9%8Analyst ForecastInsider Trade1.31%WSTWest Pharmaceutical Services$315.29+1.2%4.9689 of 5 stars2.67$460.33 46.0%3Analyst Revision1.13%SLNSilence Therapeutics$6.60-4.8%3.646 of 5 stars3.00$57.20 766.7%6Analyst ForecastNews Coverage1.02%MDGLMadrigal Pharmaceuticals$318.23+0.4%3.784 of 5 stars2.69$347.33 9.1%13Analyst Forecast0.98%EWTXEdgewise Therapeutics$32.26+1.0%1.7413 of 5 stars3.00$38.40 19.0%50.96%SLNOSoleno Therapeutics$54.55-0.5%4.0001 of 5 stars3.14$74.83 37.2%70.94%NARIInari Medical$49.58+1.2%3.2625 of 5 stars2.45$58.89 18.8%11Insider TradePositive News0.94%VKTXViking Therapeutics$51.56+0.1%4.7807 of 5 stars3.09$109.80 113.0%11Analyst Forecast0.71%TERNTerns Pharmaceuticals$5.604.327 of 5 stars2.83$27.25 386.6%60.69%VERVVerve Therapeutics$4.49-1.3%2.4352 of 5 stars3.00$25.75 473.5%40.48%CRBPCorbus Pharmaceuticals$16.48+2.5%4.8777 of 5 stars3.13$65.86 299.6%8Positive News0.40%TNYATenaya Therapeutics$2.14-3.6%3.9769 of 5 stars3.00$14.75 589.3%7Gap Up0.30%RANIRani Therapeutics$2.03-1.0%3.1632 of 5 stars3.14$11.71 477.1%7Analyst Forecast This page (NASDAQ:HRTS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Cardiovascular and Metabolics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Cardiovascular and Metabolics ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HRTS Stock Alerts